Showing 1911-1920 of 5696 results for "".
- Opthea Announces Financing Deals for OPT-302 in Wet AMDhttps://modernod.com/news/opthea-announces-financing-deals-for-opt-302-in-wet-amd/2481027/Opthea announced two financing deals aimed at advancing OPT-302, a drug candidate for wet age-related macular degeneration (AMD). Opthea announced a nondilutive financing transaction for up to $170 million from investment funds working with Launch Therapeutics to finance and advance the
- High-Tech Imaging Offers New Way to Detect Signs of Early Glaucomahttps://modernod.com/news/high-tech-imaging-offers-new-way-to-detect-signs-of-early-glaucoma/2481008/A new, noninvasive ocular imaging method may be able to detect an early indicator of glaucoma in time to prevent disease progression and vision loss, according to a new study from New York Eye and Ear Infirmary of Mount Sinai (NYEE). The study was published in the July/August issue of Op
- New App Designed to Use Artificial Intelligence to Reduce Digital Eye Strainhttps://modernod.com/news/new-app-designed-to-use-artificial-intelligence-to-reduce-digital-eye-strain/2481004/Robin Kuriakose, MD, a fellow physician in cornea and refractive surgery at the Northwestern Memorial Hospital, has launched SightKick, a new MacOS application designed to reduce digital eye strain: SightKick. Digital eye strain is a gr
- Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseaseshttps://modernod.com/news/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases/2480977/Avista Therapeutics, which recently launched as a spinout of the University of Pittsburgh Medical Center (UPMC), announced a partnership with Roche to develop novel AAV gene therapy vectors for the eyes. The partnership aims to apply Avista’s single-cell adeno-associated
- Bausch + Lomb and Novaliq Submit New Drug Application for Investigational NOV03 for Dry Eye Disease Associated with MGDhttps://modernod.com/news/bausch-lomb-and-novaliq-submission-new-drug-application-for-investigational-nov03-for-dry-eye-disease-associated-with-mgd/2480972/Bausch + Lomb and Novaliq announced the submission of a new drug application (NDA) at the end of June to FDA seeking approval for NOV03 (perfluorohexyloctane), an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease (DED) associated
- Novartis Receives FDA Approval of Beovu for the Treatment of Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-fda-approval-of-beovu-for-the-treatment-of-diabetic-macular-edema/2480891/Novartis announced that the FDA has approved Beovu (brolucizumab-dbll) 6 mg for the treatment of diabetic macular edema (DME). Today’s approval represents the second FDA-approved indication for Beovu, which was first approved for the treatment of wet age-related macular degeneration in
- Belkin Vision's Automated, Non-Contact Glaucoma Laser Treatment Receives CE Markhttps://modernod.com/news/belkin-visions-eagle-receives-ce-mark-under-mdr/2480859/Israel-based Belkin Vision announced that it has received CE Mark for its Eagle device, making it the first automated, non-contact glaucoma laser treatment available within Europe. The CE Mark was granted under Medical Device Regulation (MDR) from its notified body DEKRA.
- Stoke Therapeutics Presents New In-Vivo Data Demonstrating Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002https://modernod.com/news/stoke-therapeutics-presents-new-in-vivo-data-demonstrating-dose-related-target-engagement-and-opa1-protein-upregulation-in-retinal-tissue-following-administration-of-stk-002/2480831/Stoke Therapeutics announced new preclinical data that demonstrated dose-related target engagement and increases in OPA1 protein levels in retinal tissue of non-human primates (NHPs) following intravitreal (IVT) administration of STK-002. Target engagement and OPA1 protein increases were sus
- Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational NOV03 at ASCRShttps://modernod.com/news/bausch-lomb-presents-data-from-first-pivotal-phase-3-trial-of-investigational-nov03-at-ascrs/2480800/Bausch + Lomb and Novaliq announced that data from the first pivotal phase 3 trial (GOBI) of NOV03 (perfluorohexyloctane), which is being investigated as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibom
- Orasis Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopiahttps://modernod.com/news/orasis-announces-positive-phase-3-topline-results-of-novel-eye-drop-candidate-csf-1-for-the-treatment-of-presbyopia/2480784/Orasis Pharmaceuticals announced that the phase 3 NEAR-1 and NEAR-2 clinical trials, which evaluated the efficacy and safety of CSF-1, its novel eye drop candidate, met their primary and key secondary endpoints. Additional details of these trials will be presented at future medical meet